Last reviewed · How we verify
Parecoxib and Celecoxib
Both parecoxib and celecoxib selectively inhibit cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.
Both parecoxib and celecoxib selectively inhibit cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain. Used for Acute postoperative pain (parecoxib), Rheumatoid arthritis (celecoxib), Osteoarthritis (celecoxib).
At a glance
| Generic name | Parecoxib and Celecoxib |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Rheumatology, Inflammation |
| Phase | FDA-approved |
Mechanism of action
These are selective COX-2 inhibitors (coxibs) that preferentially block COX-2 over COX-1, thereby reducing inflammatory prostaglandins while theoretically sparing gastric protection from COX-1 inhibition. Parecoxib is the intravenous prodrug of valdecoxib, while celecoxib is an oral selective COX-2 inhibitor. Both are used for acute pain and inflammatory conditions.
Approved indications
- Acute postoperative pain (parecoxib)
- Rheumatoid arthritis (celecoxib)
- Osteoarthritis (celecoxib)
- Acute pain and fever (both agents)
Common side effects
- Hypertension
- Edema
- Dyspepsia
- Cardiovascular events (thrombotic)
- Renal impairment
Key clinical trials
- A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery (NA)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- 2% Lidocaine Gel in Reducing Postoperative Pain Following Haemorrhoidectomy (NA)
- Opioid-Sparing Protocol Comparing With Opioid-based Protocol After Bilateral Total Knee Arthroplasty (PHASE4)
- Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure (PHASE3)
- Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients (PHASE4)
- The Effect of Parecoxib Sodium Intravenous Patient-controlled Analgesia in Laparotomic Liver Resection (NA)
- Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Parecoxib and Celecoxib CI brief — competitive landscape report
- Parecoxib and Celecoxib updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI